Purpose Of Review: In this article, we will briefly review the current treatment landscape for metastatic melanoma and provide a comprehensive update on emerging novel treatment strategies.
Recent Findings: Over the past decade, remarkable advances in immunotherapy and targeted therapy have greatly improved outcomes for patients with advanced melanoma. Although a subset of patients is able to achieve durable responses, the majority experience eventual disease progression on existing therapies. Trials evaluating novel combinatorial strategies, checkpoint inhibitors, immune agonists, T cell-based therapies, intratumoral agents, and others are ongoing. While strides have been made in the treatment of advanced melanoma, further research is needed to identify alternative immune and molecular targets in order to overcome resistance and achieve better clinical outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11912-019-0849-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neoadjuvant treatment in advanced resectable melanoma and the need for a predictive biomarker - is pathologic complete response (pCR) the answer?
Am J Surg
January 2025
University of Michigan, Department of Medicine, Division of Medical Oncology, Ann Arbor, MI, USA; University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
Case report: Study of a bulky melanoma mimicking sarcoma.
Int J Surg Case Rep
January 2025
Department of Head and Neck Surgery, Institut de Cancérologie de Lorraine, 6 avenue de Bourgogne, 54519 Vandœuvre-lès-Nancy, France; CRAN, CNRS, UMR 7039, Université de Lorraine, Vandœuvre-lès-Nancy, France; Faculté d'odontologie de Lorraine, Université de Lorraine, Vandœuvre-lès-Nancy, France.
Introduction: Large melanomas, while relatively uncommon, present significant diagnostic challenges due to their size and potential to mimic other malignancies, leading to delays in appropriate treatment. Initial misdiagnosis is a substantial concern, impacting patient outcomes. This case highlights the importance of immunohistochemistry in cancer diagnosis, and of appropriate therapeutic management, which here included excision surgery of the tumor mass.
View Article and Find Full Text PDFMultidisciplinary Vulvar Cancer Management: The Dermatologist's Perspective.
Life (Basel)
December 2024
Department of Dermatology, Hospital Universitario San Cecilio, Avenida del Conocimiento s/n, 18016 Granada, Spain.
Vulvar cancer, particularly squamous cell carcinoma (SCC) and melanoma, poses significant diagnostic and therapeutic challenges due to its complex presentation and high rates of postoperative complications. Effective management requires a multidisciplinary approach, integrating the expertise of gynecologic oncologists, dermatologists, plastic surgeons, and other specialists. This review highlights the dermatologist's role in supporting early diagnosis, addressing predisposing conditions such as lichen sclerosus, and managing postoperative wound complications, including surgical site infections and dehiscence.
View Article and Find Full Text PDFDetection of Circulating Tumor DNA in Liquid Biopsy: Current Techniques and Potential Applications in Melanoma.
Int J Mol Sci
January 2025
August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Rosselló 149, 08036 Barcelona, Spain.
The treatment landscape for advanced melanoma has transformed significantly with the advent of BRAF and MEK inhibitors (BRAF/MEKi) targeting V600 mutations, as well as immune checkpoint inhibitors (ICI) like anti-PD-1 monotherapy or its combinations with anti-CTLA-4 or anti-LAG-3. Despite that, many patients still do not benefit from these treatments at all or develop resistance mechanisms. Therefore, prognostic and predictive biomarkers are needed to identify patients who should switch or escalate their treatment strategies or initiate an intensive follow-up.
View Article and Find Full Text PDFAn Optimized NGS Workflow Defines Genetically Based Prognostic Categories for Patients with Uveal Melanoma.
Biomolecules
January 2025
Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
Background: Despite advances in uveal melanoma (UM) diagnosis and treatment, about 50% of patients develop distant metastases, thereby displaying poor overall survival. Molecular profiling has identified several genetic alterations that can stratify patients with UM into different risk categories. However, these genetic alterations are currently dispersed over multiple studies and several methodologies, emphasizing the need for a defined workflow that will allow standardized and reproducible molecular analyses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!